Aprea Therapeutics Inc. has entered into a material transfer agreement with MD Anderson Cancer Center that will support investigation of APR-1051 as a potential treatment for head and neck squamous ...

Mindrank Ltd. has announced that the FDA has cleared the company’s IND application for MRANK-106, a potentially first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the ...

Improved safety window compared to single-target WEE1 inhibitors The Phase I clinical trial, set to launch in 2025, will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with ...

DENALI Part 1b results are exciting as they show that the WEE1 inhibitor, azenosertib, is active in a Cyclin E1 biomarker selective population potentially addressing a clinical unmet need.” ...

Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects Superior efficacy as a single agent and in combination therapies across various cancer models Preferential ...

Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROCPreclinical data of azenosertib demonstrating ...